N/A N=186 Sibling-Support for Adolescent Girls (SSAGE)
Anxiety · Depression · Mental Illness
Primary: Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Level 1 Cross-Cutting Symptom — 44; 42; 24; 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra Lenses
Contact Lens Wearer
Primary: Normalized logMAR Visual Acuity — 0.005; 0.003; -0.001; 0.008 LogMAR units
Phase 4 N=79 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
Microlaryngoscopy · Rigid Bronchoscopy
Primary: Time to Extubation After End of Procedure — 11.06; 10.36 Minutes
N/A N=11 Cerebrovascular Dysregulation in Chronic Kidney Disease
Chronic Kidney Diseases
Primary: Mean Arterial Pressure-Middle Cerebral Artery Blood Velocity Very Low Frequency Phase (Radians) — 1.38; 1.12; 1.40; 1.60 Radians — p=0.05
Phase 3 N=1,240 Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
Human Papillomavirus-Related Cervical Carcinoma
Primary: Number Seropositive for HPV16 at 36 Months — 538; 366 Participants
Phase 3 N=8 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Hypoglycemia · Type 1 Diabetes
Primary: Change From Baseline in Plasma Glucose Concentration at 30 Minutes After IMP Injection — 102.3; 104.3 milligrams per deciliter (mg/dL)
N/A N=302 A Needs-focused Palliative Care Intervention for Older Adults in ICUs
Palliative Care · Critical Illness · Aging
Primary: Needs; Existential Concerns; Symptoms; and Therapeutic Interaction (NEST) Scale Total Score — 28.5; 29.3 score on a scale — p=1.00
N/A N=30 Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Cataract
Primary: Binocular Distance-corrected Near (40 cm) Visual Acuity — 0.00 logMAR
Phase 2 N=37 Skin bioMARkers for Atopic Eczema Therapy Evaluation
Atopic Eczema/Dermatitis (Non-Specific)
Primary: Change in Epidermal Thickness — -31.66; -13.76; -28.65; -14.41 µm
Phase 2 N=507 Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Obesity · Obese · Overweight or Obesity
Primary: Change From Baseline in Body Weight at Week 48 — -3.31; -5.99; -9.25; -9.76 kilogram (kg) — p=<0.001
N/A N=56 Orange Juice And Sugar Intervention Study
Cardiovascular Risk Factor · Type2 Diabetes Mellitus · Insulin Sensitivity
Primary: Fasting Low Density Lipoprotein Cholesterol (LDL-C) — 5.5; 5.8 mg/dl — p=0.88
N/A N=328 RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
Long COVID · Long COVID-19 · Long COVID19
Primary: Total Number of Participants Enrolled in Each Appendix — 64; 67; 66; 66 Participants
N/A N=29 Bringing Education Through Technology, Empathic Listening, and Research
Pregnancy Related
Primary: Feasibility of the Intervention — 21.5; 21.2 score on a scale
Phase 4 N=61 Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
HIV
Primary: Proportion of Patients Free of Treatment Failure (Noncompleter = Failure) at 24 Weeks. — 30; 31; 0; 0 Participants
Phase 2 N=33 Latent Aging Mechanisms in Pain and Sleep
Chronic Pain
Primary: The Pittsburgh Sleep Quality Index (PSQI): PSQI Total Score at Baseline — 11.20; 9.78 Score on scale